Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FOXO Technologies sits at the crossroads of epigenetics and life insurance, so its SEC filings blend biotech R&D language with actuarial detail. For analysts trying to track patent milestones alongside reinsurance agreements, parsing a 300-page 10-K can feel overwhelming. Questions like “where do I see FOXO insider trading Form 4 transactions?” or “how is DNA-methylation research funded this quarter?” quickly surface. That complexity is why many investors start their research here.
Stock Titan’s AI reads every FOXO quarterly earnings report 10-Q filing the moment it hits EDGAR and distills the revenue shifts, cash-burn trends, and regulatory notes into plain English. Need a quick brief? Our platform flags FOXO 8-K material events explained in under 90 seconds, delivers FOXO Form 4 insider transactions real-time, and links each data point to the original PDF. You’ll also find an AI walkthrough that makes the FOXO annual report 10-K simplified, complete with section-by-section jump links. No more skimming footnotes to understand deferred R&D tax credits or goodwill tests—our expert analysis highlights them for you.
Because FOXO is pioneering longevity underwriting, its proxy statement executive compensation tables reveal how management is incentivized to hit biomarker validation goals, while the FOXO earnings report filing analysis shows progress on lab commercialization. You can monitor FOXO executive stock transactions Form 4 before capital raises, compare cohort survival models across filings, and export the numbers for your own models. Whether you’re focused on understanding FOXO SEC documents with AI or just need a single ratio for tomorrow’s pitch, every disclosure is indexed, searchable, and continuously updated. Explore the complete FOXO library—10-K, 10-Q, 8-K, S-1, and more—FOXO SEC filings explained simply.
FOXO Technologies (NYSE:FOXO) amended its Certificate of Incorporation on June 25 2025 to authorize up to 4,000,000 shares of Series E Cumulative Redeemable Secured Preferred Stock. The new series carries a $25.00 liquidation preference, semi-annual cumulative cash dividends plus stock dividends, is non-voting and non-convertible, and is secured by the stock of wholly-owned FOXO Acquisition Corp. The authorization gives the board flexibility to raise roughly $100 million in preferred equity while ranking senior to common stock. A press release (Ex. 99.1) announcing the designation was furnished under Item 7.01; no financial statements were included.
FOXO Technologies (NYSE American: FOXO) filed an 8-K reporting that a stockholder holding 82.08% of voting power delivered written consent approving nine share-related actions.
- Items 1-7: Authorize issuance of >20% of outstanding shares upon conversion of Series A-D preferred stock, convertible notes, an exchange agreement, finder fees and inducement shares, satisfying NYSE American Section 713.
- Item 8: Issue 40,000 shares to director Bret Barnes under his agreement, per Section 711.
- Item 9: Permit a reverse stock split at a 1-for-1.99 ratio any time before 6 Nov 2025 at the board’s discretion.
A preliminary Schedule 14C has been filed; actions become effective 20 days after mailing the definitive statement.
FOXO Technologies has announced major corporate actions approved by written consent of its majority shareholder on June 23, 2025. The key approvals include:
- Share Issuance Authorizations: Approval for converting multiple series of preferred stock (Series A, B, C, D) into Class A Common Stock, which may exceed 20% of outstanding shares
- Convertible Notes: Approval for issuing common shares from conversion of promissory notes and inducement shares
- Strategic Agreements: Approval for share issuances under the Smithline Family Trust II Exchange Agreement and J.H. Darbie finder's agreements
- Director Compensation: Approval to issue 40,000 common shares to director Bret Barnes
- Reverse Stock Split: Authorization for a 1:1.99 reverse split to be implemented before November 6, 2025
These actions are being taken to comply with NYSE American listing requirements, particularly Sections 711 and 713, regarding stockholder approval for significant share issuances and equity compensation arrangements. No stockholder meeting will be held as majority consent has been obtained.
FOXO Technologies Inc. filed a Form D to report the completion of a private placement exempt under Rule 506(b) and Securities Act Section 4(a)(5). The notice indicates that on 3 June 2025 the company sold its entire $1.65 million offering of Series A Preferred Stock. The transaction was concluded with one accredited investor; no sales remain open and the offering is not expected to last beyond one year.
The issuer is a Delaware corporation formed in 2020 and is now headquartered at 477 South Rosemary Avenue, Suite 224, West Palm Beach, FL. Executive leadership disclosed in the filing includes Seamus Lagan (Chief Executive Officer & Interim CFO), Chairman Trevor Langley, and directors Mark White, Bret Barnes, and Francis Colt deWolf III.
- Offering size: $1,650,000 fully subscribed
- Security type: Equity – Series A Preferred Stock
- Investors: 1 (all accredited)
- Commissions / Finder fees: $0
- Proceeds to insiders: $0
- Issuer size: Revenue and asset ranges declined to disclose
The company incurred no brokerage or placement-agent expenses, preserving the full proceeds for corporate use. Because the issuer chose not to reveal revenue or asset ranges, the filing provides no direct insight into current operating scale or liquidity needs. Nonetheless, the completed capital raise under a widely used exemption signals that FOXO successfully accessed private funding without immediate public dilution.
FAQ
What is the current stock price of FOXO TECHNOLOGIES (FOXO)?
What is the market cap of FOXO TECHNOLOGIES (FOXO)?
What is the main focus of FOXO Technologies?
What are the primary business segments of FOXO Technologies?
How does FOXO Technologies utilize epigenetic data?
How does FOXO differentiate itself from competitors?
Who are the primary customers of FOXO Technologies?
What strategic initiatives support FOXO's business model?
What technological innovations are central to FOXO's operations?
How does FOXO ensure the reliability of its solutions?
